Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYZK4776
Stock Name / FundiShares Healthcare Innovation UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerDRDR(GBX) LSE
ETF Ticker2B78(EUR) F
ETF Ticker2B78.DE(EUR) CXE
ETF TickerDRDR.LS(GBX) CXE
ETF TickerHEAL.AS(EUR) CXE
ETF TickerHEAL.LS(USD) CXE
ETF TickerHEALz(USD) CXE
ETF TickerHEAL(EUR) ETF Plus
ETF TickerDRDR.L(GBP) LSE

Holdings detail for ACAD

Stock NameACADIA Pharmaceuticals Inc
TickerACAD(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS0042251084
LEI529900O3044NO0PEA039

Show aggregate ACAD holdings

News associated with ACAD

Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $28.88
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nineteen brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has […] - 2025-09-12 02:48:53
UBS Group Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its price target increased by investment analysts at UBS Group from $36.00 to $39.00 in a report issued on Tuesday, MarketBeat Ratings reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. UBS Group’s price objective indicates a potential upside of 63.87% from the […] - 2025-09-11 02:49:04
Deutsche Bank AG Has $12.63 Million Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Deutsche Bank AG trimmed its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 27.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 760,594 shares of the biopharmaceutical company’s stock after selling 281,853 shares during the period. Deutsche Bank AG owned […] - 2025-08-15 05:17:01
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Holdings Boosted by Zurcher Kantonalbank Zurich Cantonalbank
Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 14.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 27,256 shares of the biopharmaceutical company’s stock after purchasing an additional 3,389 shares during the period. […] - 2025-08-08 04:56:48
Mackenzie Financial Corp Grows Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Mackenzie Financial Corp boosted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 14.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 58,379 shares of the biopharmaceutical company’s stock after buying an additional 7,314 shares during the period. Mackenzie […] - 2025-08-06 04:36:58
Envestnet Asset Management Inc. Buys 36,003 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Envestnet Asset Management Inc. increased its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 33.8% during the 1st quarter, HoldingsChannel.com reports. The fund owned 142,667 shares of the biopharmaceutical company’s stock after acquiring an additional 36,003 shares during the period. Envestnet Asset Management Inc.’s holdings in ACADIA Pharmaceuticals were worth $2,370,000 […] - 2025-07-29 04:08:59
Analysts Predict 15% Upside For The Holdings of IJR
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-28 10:46:16
Cerity Partners LLC Sells 3,872 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Cerity Partners LLC trimmed its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 18.9% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 16,587 shares of the biopharmaceutical company’s stock after selling 3,872 shares during the period. Cerity Partners LLC’s holdings in ACADIA Pharmaceuticals were […] - 2025-07-28 04:46:48
Xponance Inc. Acquires 1,434 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Xponance Inc. boosted its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 14.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 11,585 shares of the biopharmaceutical company’s stock after purchasing an additional 1,434 shares during the quarter. Xponance Inc.’s holdings in ACADIA Pharmaceuticals were worth $192,000 as of its […] - 2025-07-21 06:12:11
Bank of New York Mellon Corp Boosts Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Bank of New York Mellon Corp boosted its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 96.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 804,390 shares of the biopharmaceutical company’s stock after acquiring an additional 394,640 shares during […] - 2025-07-21 04:30:53
New York State Teachers Retirement System Grows Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
New York State Teachers Retirement System grew its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 547.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,625 shares of the biopharmaceutical company’s stock after acquiring an additional 28,435 shares during […] - 2025-07-11 05:34:49
72,125 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Acquired by Illinois Municipal Retirement Fund
Illinois Municipal Retirement Fund bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 72,125 shares of the biopharmaceutical company’s stock, valued at approximately $1,198,000. Other […] - 2025-07-02 05:28:55
SG Americas Securities LLC Sells 2,465,581 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
SG Americas Securities LLC decreased its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 99.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,150 shares of the biopharmaceutical company’s stock after selling 2,465,581 shares during the quarter. SG Americas […] - 2025-06-27 04:18:48
State of Alaska Department of Revenue Invests $1.13 Million in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
State of Alaska Department of Revenue purchased a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) during the 1st quarter, HoldingsChannel.com reports. The firm purchased 68,225 shares of the biopharmaceutical company’s stock, valued at approximately $1,133,000. Several other hedge funds and other institutional investors have also recently modified their holdings of ACAD. Principal […] - 2025-06-26 04:43:03
Royal Bank Of Canada Forecasts Strong Price Appreciation for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its target price raised by stock analysts at Royal Bank Of Canada from $26.00 to $38.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective indicates a potential upside of […] - 2025-06-25 02:36:49
KMDA vs. ACAD: Which Stock Is the Better Value Option?
KMDA vs. ACAD: Which Stock Is the Better Value Option? - 2025-06-18 12:40:06
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Director Sells $314,633.88 in Stock
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) Director Laura Brege sold 14,446 shares of the firm’s stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $21.78, for a total value of $314,633.88. Following the completion of the sale, the director now directly owns 15,095 […] - 2025-06-09 05:36:49
ProShare Advisors LLC Has $763,000 Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
ProShare Advisors LLC increased its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 28.3% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 41,580 shares of the biopharmaceutical company’s stock after purchasing an additional 9,164 shares during the period. ProShare Advisors LLC’s holdings in ACADIA Pharmaceuticals were worth $763,000 […] - 2025-05-25 06:03:26
Bank of America Corp DE Grows Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Bank of America Corp DE raised its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 41.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 680,853 shares of the biopharmaceutical company’s stock after acquiring an additional 199,504 shares during the quarter. Bank of America Corp DE’s holdings in ACADIA Pharmaceuticals were worth […] - 2025-05-23 05:19:06
ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $24.00
ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its target price lifted by Morgan Stanley from $20.00 to $24.00 in a research report sent to investors on Tuesday morning,Benzinga reports. Morgan Stanley currently has an equal weight rating on the biopharmaceutical company’s stock. A number of other research analysts have also issued reports on ACAD. Wall […] - 2025-05-23 02:52:57
ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $35.00 at Deutsche Bank Aktiengesellschaft
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its price objective upped by research analysts at Deutsche Bank Aktiengesellschaft from $20.00 to $35.00 in a research note issued on Wednesday, MarketBeat reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective points to a potential upside of […] - 2025-05-23 02:52:50
ACADIA Pharmaceuticals (NASDAQ:ACAD) Trading Up 3.5% Following Analyst Upgrade
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) was up 3.5% during mid-day trading on Wednesday after Wall Street Zen upgraded the stock from a hold rating to a buy rating. The stock traded as high as $22.75 and last traded at $22.44. Approximately 376,453 shares traded hands during mid-day trading, a decline of 84% […] - 2025-05-23 02:03:06
ACADIA Pharmaceuticals (NASDAQ:ACAD) Upgraded to Buy at StockNews.com
StockNews.com upgraded shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) from a hold rating to a buy rating in a report issued on Wednesday. Several other brokerages have also commented on ACAD. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $26.00 price objective on shares of ACADIA Pharmaceuticals in a research report […] - 2025-05-22 04:50:50
ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $32.00 Price Target at HC Wainwright
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its target price increased by equities researchers at HC Wainwright from $27.00 to $32.00 in a research report issued on Monday, MarketBeat Ratings reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 47.53% […] - 2025-05-21 02:42:45
Robert W. Baird Raises ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $31.00
ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price target raised by Robert W. Baird from $28.00 to $31.00 in a report issued on Monday,Benzinga reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock. A number of other research firms also recently issued reports on ACAD. BMO Capital Markets increased their […] - 2025-05-20 02:36:58
Northern Trust Corp Has $22.61 Million Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Northern Trust Corp increased its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 9.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,232,366 shares of the biopharmaceutical company’s stock after buying an additional 106,236 shares during the period. Northern Trust Corp owned 0.74% […] - 2025-05-13 06:14:59
Traders Purchase Large Volume of ACADIA Pharmaceuticals Call Options (NASDAQ:ACAD)
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) saw unusually large options trading activity on Thursday. Stock traders purchased 2,626 call options on the company. This is an increase of 146% compared to the average daily volume of 1,068 call options. Insider Buying and Selling In other news, Director Elizabeth A. Garofalo sold 4,919 shares […] - 2025-05-09 02:38:58
Envestnet Asset Management Inc. Decreases Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Envestnet Asset Management Inc. lessened its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 10.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 106,664 shares of the biopharmaceutical company’s stock after selling 12,037 shares during the quarter. Envestnet Asset […] - 2025-04-28 04:38:49
Legal & General Group Plc Sells 2,348 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Legal & General Group Plc cut its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 1.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 133,042 shares of the biopharmaceutical company’s stock after selling 2,348 shares during the quarter. Legal & General […] - 2025-04-25 05:16:54
Cerity Partners LLC Acquires 6,173 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Cerity Partners LLC increased its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 43.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,459 shares of the biopharmaceutical company’s stock after acquiring an additional 6,173 shares during the quarter. […] - 2025-04-24 04:52:50

iShares Healthcare Innovation UCITS ETF USD (Acc) ACAD holdings

DateNumber of ACAD Shares HeldBase Market Value of ACAD SharesLocal Market Value of ACAD SharesChange in ACAD Shares HeldChange in ACAD Base ValueCurrent Price per ACAD Share HeldPrevious Price per ACAD Share Held
2025-11-11 (Tuesday)149,757USD 3,552,236ACAD holding increased by 227631USD 3,552,2360USD 227,631 USD 23.72 USD 22.2
2025-11-10 (Monday)149,757USD 3,324,605ACAD holding decreased by -55410USD 3,324,6050USD -55,410 USD 22.2 USD 22.57
2025-11-07 (Friday)149,757USD 3,380,015ACAD holding increased by 137776USD 3,380,0150USD 137,776 USD 22.57 USD 21.65
2025-11-06 (Thursday)149,757USD 3,242,239ACAD holding decreased by -101835USD 3,242,2390USD -101,835 USD 21.65 USD 22.33
2025-11-05 (Wednesday)149,757USD 3,344,074ACAD holding increased by 71884USD 3,344,0740USD 71,884 USD 22.33 USD 21.85
2025-11-04 (Tuesday)149,757USD 3,272,190ACAD holding decreased by -77874USD 3,272,1900USD -77,874 USD 21.85 USD 22.37
2025-11-03 (Monday)149,757USD 3,350,064ACAD holding decreased by -49420USD 3,350,0640USD -49,420 USD 22.37 USD 22.7
2025-10-31 (Friday)149,757USD 3,399,484ACAD holding decreased by -5990USD 3,399,4840USD -5,990 USD 22.7 USD 22.74
2025-10-30 (Thursday)149,757USD 3,405,474ACAD holding increased by 31449USD 3,405,4740USD 31,449 USD 22.74 USD 22.53
2025-10-29 (Wednesday)149,757USD 3,374,025ACAD holding decreased by -13478USD 3,374,0250USD -13,478 USD 22.53 USD 22.62
2025-10-28 (Tuesday)149,757USD 3,387,503ACAD holding decreased by -55410USD 3,387,5030USD -55,410 USD 22.62 USD 22.99
2025-10-27 (Monday)149,757USD 3,442,913ACAD holding increased by 145264USD 3,442,9130USD 145,264 USD 22.99 USD 22.02
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ACAD by Blackrock for IE00BYZK4776

Show aggregate share trades of ACAD

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-10-24SELL-1,27222.02022.190 22.173USD -28,204 18.84 Loss of -4,241 on sale
2025-09-11BUY63724.20024.460 24.434USD 15,564 18.47
2025-07-08SELL-63621.02021.170 21.155USD -13,455 18.04 Loss of -1,981 on sale
2025-06-24SELL-63922.41022.700 22.671USD -14,487 17.81 Loss of -3,106 on sale
2025-06-23SELL-63922.48023.040 22.984USD -14,687 17.78 Loss of -3,327 on sale
2025-06-11SELL-63722.30022.560 22.534USD -14,354 17.50 Loss of -3,209 on sale
2025-05-30SELL-63721.57022.400 22.317USD -14,216 17.22 Loss of -3,249 on sale
2025-05-21BUY63721.85022.750 22.660USD 14,434 16.93
2025-05-14SELL-3,82217.16017.620 17.574USD -67,168 16.84 Loss of -2,819 on sale
2025-04-30SELL-63714.60014.650 14.645USD -9,329 16.94 Profit of 1,462 on sale
2025-04-28SELL-63714.66015.020 14.984USD -9,545 16.99 Profit of 1,276 on sale
2025-04-25SELL-63714.73014.830 14.820USD -9,440 17.01 Profit of 1,395 on sale
2025-04-11SELL-3,84614.58014.610 14.607USD -56,179 17.21 Profit of 10,025 on sale
2025-04-08SELL-1,91714.10015.220 15.108USD -28,962 17.31 Profit of 4,219 on sale
2025-04-07BUY3,37914.61015.700 15.591USD 52,682 17.34
2025-03-31SELL-1,24216.61016.880 16.853USD -20,931 17.39 Profit of 670 on sale
2025-03-21SELL-1,23816.79017.310 17.258USD -21,365 17.42 Profit of 197 on sale
2025-03-12SELL-62416.77017.400 17.337USD -10,818 17.44 Profit of 67 on sale
2025-02-28SELL-62419.60019.620 19.618USD -12,242 17.38 Loss of -1,397 on sale
2025-02-25BUY62419.01019.720 19.649USD 12,261 17.29
2025-02-20SELL-62420.29020.430 20.416USD -12,740 17.15 Loss of -2,035 on sale
2025-02-19BUY1,24619.67020.060 20.021USD 24,946 17.11
2025-02-18BUY62419.74020.290 20.235USD 12,627 17.06
2024-12-30BUY3,66116.69016.810 16.798USD 61,497 16.06
2024-12-06SELL-59917.28017.360 17.352USD -10,394 15.86 Loss of -894 on sale
2024-12-04SELL-59917.17017.260 17.251USD -10,333 15.79 Loss of -877 on sale
2024-12-03SELL-1,19816.30016.580 16.552USD -19,829 15.77 Loss of -938 on sale
2024-11-21SELL-60516.18016.420 16.396USD -9,920 15.46 Loss of -566 on sale
2024-11-20SELL-61516.27016.390 16.378USD -10,072 15.42 Loss of -592 on sale
2024-11-19SELL-61516.21017.030 16.948USD -10,423 15.37 Loss of -971 on sale
2024-11-18SELL-2,40417.03017.170 17.156USD -41,243 15.27 Loss of -4,546 on sale
2024-11-12SELL-60117.93018.400 18.353USD -11,030 15.09 Loss of -1,963 on sale
2024-11-07SELL-60117.20017.490 17.461USD -10,494 14.73 Loss of -1,643 on sale
2024-11-05SELL-1,20215.00015.030 15.027USD -18,062 14.61 Loss of -507 on sale
2024-10-28SELL-60314.74014.810 14.803USD -8,926 14.48 Loss of -196 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ACAD

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19177,131200310,62757.0%
2025-09-18231,742428554,08241.8%
2025-09-17277,075374461,41860.0%
2025-09-16292,1342,622560,92052.1%
2025-09-15608,4886,4161,142,65153.3%
2025-09-12234,4780584,49240.1%
2025-09-11237,3450578,23341.0%
2025-09-10406,173918959,74342.3%
2025-09-09416,1928,8751,219,14834.1%
2025-09-08275,369917543,61350.7%
2025-09-05203,9924,543403,13850.6%
2025-09-04357,54611,463821,94843.5%
2025-09-03165,7670471,56735.2%
2025-09-02379,278123,302944,99440.1%
2025-08-29178,641647380,60446.9%
2025-08-28347,63242,128704,63949.3%
2025-08-27735,31273,2711,108,40266.3%
2025-08-26383,1131,531782,12849.0%
2025-08-25415,483632763,46054.4%
2025-08-22927,9488131,757,01352.8%
2025-08-21224,0110400,36456.0%
2025-08-20121,997202279,17143.7%
2025-08-19231,0800456,08150.7%
2025-08-18679,222196963,98270.5%
2025-08-15641,9945,137984,48965.2%
2025-08-14332,2470569,26758.4%
2025-08-13267,7031,852555,59948.2%
2025-08-12505,5096,990849,12559.5%
2025-08-11257,1302,117493,09352.1%
2025-08-08313,38073531,75358.9%
2025-08-07381,3323,323621,47361.4%
2025-08-06256,267142516,14149.7%
2025-08-05314,036470596,27852.7%
2025-08-04265,143235549,94748.2%
2025-08-01242,661100835,08329.1%
2025-07-31356,257876685,25052.0%
2025-07-30515,390335843,65661.1%
2025-07-29280,2576,520405,60769.1%
2025-07-28328,072654464,16570.7%
2025-07-25169,8180295,05557.6%
2025-07-24304,7731,105461,02066.1%
2025-07-23228,9071,204403,50156.7%
2025-07-22159,5511,542259,14561.6%
2025-07-21214,5211304,30870.5%
2025-07-18165,6362,788227,87372.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.